Next Article in Journal
The Isolated in Utero Environment Is Conducive to the Emergence of RNA and DNA Virus Variants
Previous Article in Journal
Hypericin Inhibit Alpha-Coronavirus Replication by Targeting 3CL Protease
 
 
Article

Compassionate Use of GC5131 (Hyperimmunoglobulin) Therapy in Critically Ill Patients Diagnosed with COVID-19: A Case Series and Review of Literature

by 1,†, 2,† and 2,*
1
Division of Pulmonary Disease, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu 47404, Korea
2
Division of Infectious Diseases, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu 47404, Korea
*
Author to whom correspondence should be addressed.
These authors contributed equally to this study as first author.
Academic Editor: Dimitrios Paraskevis
Viruses 2021, 13(9), 1826; https://doi.org/10.3390/v13091826
Received: 21 July 2021 / Revised: 7 September 2021 / Accepted: 8 September 2021 / Published: 14 September 2021
(This article belongs to the Topic Burden of COVID-19 in Different Countries)
Presently, the use of convalescent plasma and hyperimmunoglobulin obtained from individuals who have recovered from coronavirus disease 2019 (COVID-19) has proved to potentially provide passive antibody-based immunity, thereby leading to several clinical trials to develop an immune-based COVID-19 treatment. However, the therapeutic efficacy of hyperimmunoglobulin in critically ill patients with COVID-19 remains unknown. On 23 October 2020, we first administered GC5131 in a compassionate-use program to critically ill patients at the Kyungpook National University, Chilgok Hospital, Korea. Since then, five more critically ill patients were treated with GC5131 in this compassionate-use program in our hospital up until 17 December 2020. We retrospectively reviewed the clinical responses of six critically ill patients diagnosed with COVID-19 who received the hyperimmunoglobulin concentrate, GC5131, which was produced by the Green Cross Corporation. After the administration of GC5131, five patients died due to an exacerbation of COVID-19 pneumonia. GC5131 was ineffective when administered to critically ill patients with COVID-19. Nevertheless, we propose that to expect a therapeutic effect from GC5131, it should be administered as early as possible to avoid the excessive inflammatory response phase in patients with severe and advanced COVID-19 infection. This step was difficult to achieve in the real world due to the time required for decision making and the process of the compassionate-use program. View Full-Text
Keywords: COVID-19; immunoglobulin; convalescence; plasma; clinical effectiveness COVID-19; immunoglobulin; convalescence; plasma; clinical effectiveness
Show Figures

Figure 1

MDPI and ACS Style

Choi, S.; Hwang, S.; Kwon, K. Compassionate Use of GC5131 (Hyperimmunoglobulin) Therapy in Critically Ill Patients Diagnosed with COVID-19: A Case Series and Review of Literature. Viruses 2021, 13, 1826. https://doi.org/10.3390/v13091826

AMA Style

Choi S, Hwang S, Kwon K. Compassionate Use of GC5131 (Hyperimmunoglobulin) Therapy in Critically Ill Patients Diagnosed with COVID-19: A Case Series and Review of Literature. Viruses. 2021; 13(9):1826. https://doi.org/10.3390/v13091826

Chicago/Turabian Style

Choi, Sunha, Soyoon Hwang, and Kitae Kwon. 2021. "Compassionate Use of GC5131 (Hyperimmunoglobulin) Therapy in Critically Ill Patients Diagnosed with COVID-19: A Case Series and Review of Literature" Viruses 13, no. 9: 1826. https://doi.org/10.3390/v13091826

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop